Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Nitsche C, Dobner S, Rosenblum HR, Patel KP, Longhi S, Yilmaz A, Merlo M, Papathanasiou M, Griffin J, Oerlemans MIFJ, Gama F, Hamdan A, Kelion AD, Schuster A, Glaveckaité S, Akyol N, Porcari A, Schlender L, Capovilla T, Autherith M, Hauptmann L, Halavina K, Cavalcante JL, Fontana M, Scully PR, Moon JC, Mascherbauer J, Ristl R, Biagini E, Stortecky S, Maurer MS, Treibel TA; AS-Amyloidosis Consortium.
Nitsche C, et al.
Eur Heart J. 2025 Jun 2:ehaf362. doi: 10.1093/eurheartj/ehaf362. Online ahead of print.
Eur Heart J. 2025.
PMID: 40452225
Free article.